Search clinical trials for: Integrase inhibitor

Total 64631 results

McGill University Health Centre/Research Institute...
Merck Sharp & Dohme LLC

Completed

Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection

HIV

Canada
Bristol-Myers Squibb

Withdrawn

A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects

HIV Infections
Gilead Sciences

Completed

Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART.

HIV | Human Immunodeficiency Virus | HIV-1

United States, Puerto Rico
Hoffmann-La Roche
Trimeris

Terminated

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients (AMICI)

HIV Infections

United States, Puerto Rico
Fundacion para la Investigacion Biomedica del Hospital...
Merck Sharp & Dohme LLC

Completed

ARTiBIOME: Observational Study on the Effect of HIV and ART on Gut Microbiome

HIV Infections

Spain
Helen Reynolds
Desmond Tutu HIV Centre; Infectious Disease Institute, Kampala, Uganda

Active, not recruiting

Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin (DoRIS)

Tuberculosis | Hiv

Uganda, South Africa
ViiV Healthcare
GlaxoSmithKline

Completed

A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)

Infection, Human Immunodeficiency Virus

Germany
Fundación FLS de Lucha Contra el Sida, las Enfermedades...

Completed

Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease

HIV

Spain
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

Infection, Human Immunodeficiency Virus

United States
Radboud University Medical Center
University Medical Center Groningen; Erasmus Medical Center; Leiden University...

Withdrawn

Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. (POLO)

Hepatic Impairment | HIV-1-infection
Institut de Médecine et d'Epidémiologie Appliquée...

Completed

Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV Infection (DOLUPRIM)

HIV Infection Primary
Calmy Alexandra

Completed

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients (MONODO)

Human Immunodeficiency Virus | Treatment Efficacy | Monotherapy | Dolutegravir

Switzerland
Desmond Tutu TB Centre
University of Stellenbosch; UNITAID; Chiang Mai University

Recruiting

Pharmacokinetics and Safety of DolutegravIr in Neonate (PETITE-DTG)

Hiv

South Africa
Swiss Tropical & Public Health Institute
University of Basel; Ministry of Health, Lesotho; District Health Management... and other collaborators

Completed

Dolutegravir in Real Life in Lesotho (DO-REAL)

HIV-1-infection

Lesotho
University of Nairobi
ViiV Healthcare

Completed

Second-line Switch to Dolutegravir Study (2SD)

HIV-1-infection

Kenya
St Stephens Aids Trust

Completed

Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)

HIV

Germany, Spain, France, United Kingdom, Belgium, Italy
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen. (VIKING-3)

Infection, Human Immunodeficiency Virus

United States, Spain, France, Canada, Portugal, Italy, Belgium
Cliniques universitaires Saint-Luc- Université...

Recruiting

Gut Microbiota, PGx and INSTIs Response

HIV Infections

Belgium
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

GSK1349572 Hepatic Impairment Study

HIV Infections | Healthy Subjects | Hepatic Impairment | Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare

Completed

GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study

Healthy Subjects

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Dolutegravir Expanded Access Study (DEAP)

HIV Infections | Infection, Human Immunodeficiency Virus

France, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
Nantes University Hospital

Completed

QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient (QDISS)

Virus-HIV

France
Fundacion Clinic per a la Recerca Biomédica

Unknown

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

HIV-1-infection | Solid Organ Transplant

Spain
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Tolerance and Pharmacokinetics of Raltegravir-Containing Antiretroviral Therapy in Infants, Children Infected With HIV and TB

HIV Infections | Tuberculosis

South Africa
Arbeitsgemeinschaft medikamentoese Tumortherapie
Merck Sharp & Dohme LLC

Completed

Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

HIV Infections

Austria
Shanghai Public Health Clinical Center

Unknown

Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients

HIV

China
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Mass Balance Study

Healthy Volunteer

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Etravirine

Healthy Subjects

United States
Fondazione Penta UK
UCL Great Ormond Street Institute of Child Health

Recruiting

Pregnancy and Neonatal Outcomes Following Antenatal Exposure to Raltegravir: a Pooled Analysis From the European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC)

HIV Infections

Spain, Switzerland, United Kingdom, Belgium, Italy, Romania, Russian Federation
The HIV Netherlands Australia Thailand Research...
Chulalongkorn University; National Healthcare Group Pte Ltd, Singapore

Completed

Pharmacokinetics of Low Dose Raltegravir

HIV Infections

Thailand
University of Miami
Merck Sharp & Dohme LLC

Terminated

Addition of Raltegravir to Established Antiretroviral Suppressive Therapy

HIV

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of GSK1349572 (Dolutegravir, DTG) in Healthy Japanese Subjects

Infection, Human Immunodeficiency Virus

United States
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Terminated

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Viremia | HIV-1 Infection | Treatment Resistant Disorders

France
National Institute of Neurological Disorders and...

Completed

Raltegravir for HAM/TSP

HTLV-I Infection

United States
Washington University School of Medicine
Merck Sharp & Dohme LLC

Withdrawn

Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load

Human T-cell Leukemia Virus Type 1 Infection
Community Research Initiative of New England

Completed

BRAVO: Background Regimen of Raltegravir on Virologic Outcome (BRAVO)

HIV Infections

United States
University of North Carolina, Chapel Hill
GlaxoSmithKline

Completed

GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects

Healthy Adult Females

United States
Fundacion para la Investigacion Biomedica del Hospital...
Merck Sharp & Dohme LLC

Completed

Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1

HIV Infections | HIV-1

Spain
University of Rochester
Merck Sharp & Dohme LLC

Completed

Comparing Raltegravir Genital Tract Distribution in HIV-infected Men and Women

HIV Infections

United States
GlaxoSmithKline
Shionogi

Completed

GSK1349572 Drug Interaction Study With Protease Inhibitors

Healthy Subjects | Infection, Human Immunodeficiency Virus

United States
Kelley-Ross & Associates, Inc.

Not yet recruiting

Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. (IDCaPP)

HIV Infections

United States
University of Liverpool
Liverpool School of Tropical Medicine; Desmond Tutu Health Foundation

Recruiting

Doravirine Dose Optimisation in Pregnancy (DoraDO)

HIV

South Africa
Erasmus Medical Center

Completed

The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial (DOMONO)

Human Immunodeficiency Virus

Netherlands
Fundación Pública Andaluza para la Investigación...
Merck Sharp & Dohme LLC

Unknown

Neuropsyquiatric Evolution After Introduction of Raltegravir QD in Substitution of Dolutegravir: NEAR QD Study (NEARQD)

HIV Infections

Spain
Queen Mary University of London
Merck Sharp & Dohme LLC

Completed

Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis (INSPIRE)

Relapsing Remitting Multiple Sclerosis

United Kingdom
ViiV Healthcare
Glaxosmithkline/Quintiles

Completed

A Study to Evaluate the Effect of High Fat Meal on Cabotegravir

Infection, Human Immunodeficiency Virus

United States
The Miriam Hospital
Merck Sharp & Dohme LLC; Tufts Medical Center

Completed

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

HIV Infections | HIV | Hypertriglyceridemia | Hyperlipidemia

United States
ViiV Healthcare
GlaxoSmithKline; Shionogi

Completed

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

Infection, Human Immunodeficiency Virus

United States
University of North Carolina, Chapel Hill
GlaxoSmithKline

Completed

GSK1349572 Exposure in Blood, Seminal Fluid, and Rectal Fluid and Tissue in Healthy Male Subjects

Healthy

United States
University of California, Los Angeles
University Health Network, Toronto; Merck Sharp & Dohme LLC; Tufts University; Vanderbilt... and other collaborators

Completed

Raltegravir Therapy for Women With HIV and Fat Accumulation

HIV Infections | Lipodystrophy

United States, Canada

Search clinical trials for: Integrase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations